CJC-1295 Buyer's Guide: 4 Decisions Before You Buy

Most people approaching CJC-1295 think of it as a simple upgrade over growth hormone, a cleaner way to get the same result, and that framing leads to every mistake that follows. To understand why the four decisions in this guide actually matter, you need the full map first.

Your pituitary gland releases growth hormone in pulses, not a steady stream, and those pulses are controlled by two opposing signals coming from the hypothalamus. The first signal is something called GHRH, or growth hormone releasing hormone, which tells the pituitary to fire. The second is something called somatostatin, which is the brake that shuts the pulse down and keeps the system from running continuously. CJC-1295 is a synthetic version of GHRH, so it steps on the gas. Ipamorelin works through a completely different receptor called GHSR1a, the ghrelin receptor, and it amplifies the pulse from a different angle. Used together, they push on the same outcome through two separate mechanisms, which is why the combination produces a stronger signal than either one alone. The result is your pituitary releases more of its own growth hormone, your liver responds by producing more IGF-1, and you get the downstream effects of elevated growth hormone without ever introducing synthetic growth hormone into the equation.

That distinction matters more than most people realize. And the first decision is where it starts to break down if you buy the wrong version.

CJC-1295 comes in two forms. The version with something called DAC, or Drug Affinity Complex, is chemically modified to bind to albumin proteins in your blood, which extends its half life from roughly 30 minutes to around seven days. The appeal is obvious because you only inject once or twice a week instead of daily. The problem is that a molecule that stays active for seven days does not produce a pulse. It produces a flat, sustained elevation of GHRH activity, and your pituitary is not designed to respond to a flat signal the way it responds to a sharp one. The entire argument for using a secretagogue over exogenous growth hormone is that you preserve the natural pulsatile architecture of your own GH axis. DAC removes that architecture entirely, and if a flat elevation of growth hormone is the goal, exogenous growth hormone has decades of clinical data behind it and does that job more predictably. CJC-1295 without DAC has a half life short enough that it acts closer to a pulse trigger, which is the point. No DAC is the only version that actually does what a secretagogue is supposed to do.

The second decision is about dosing math, which matters more when you are buying a pre-blended vial. A common format is five milligrams of CJC-1295 plus five milligrams of Ipamorelin in a single vial. If you reconstitute that with two milliliters of bacteriostatic water, every ten units on an insulin syringe contains 250 micrograms of each peptide. Knowing that number is not just convenient, it is the difference between dosing correctly and accidentally running twice what you intended because you calculated only one compound.

The third decision is cycling, and this is where most of the misinformation lives. The standard recommendation is three months on, one month off, and most people assume that applies equally to both peptides. It does not. CJC-1295 works through GHRH receptors, and those receptors do not desensitize in the same way under sustained stimulation. Tesamorelin, which is a stabilized GHRH analog nearly identical in mechanism to CJC-1295, was run continuously for 52 weeks in the FDA clinical trials that led to its approval, and IGF-1 levels held steady from week 26 through week 52 without any meaningful decline. That is a year of uninterrupted GHRH receptor stimulation with no loss of effect.

Ipamorelin is a different story. Ipamorelin works by activating GHSR1a, the ghrelin receptor, and that receptor undergoes a process called beta-arrestin mediated desensitization, which means the longer you stimulate it without a break, the more the cell pulls the receptor inward and off the surface, reducing the number of available binding sites. Fewer receptors on the surface means a weaker signal at the same dose. After roughly 12 to 16 weeks of continuous use, IGF-1 levels can fall 20 to 30 percent from their peak even though the dose has not changed. The cycle break is not about the CJC side at all. It is entirely about giving GHSR1a time to restore receptor density on the cell surface before you stimulate it again.

So when someone tells you that you have to cycle because the body adapts to CJC, they are technically right about the outcome but wrong about the mechanism, and that matters because if you were ever running CJC without a ghrelin receptor agonist, the cycling rationale would not apply in the same way.

The fourth decision is the one most people delay thinking about until it stops being theoretical. Secretagogues work within your biological ceiling. They make your pituitary more responsive and more productive, but the pituitary still sets the upper limit. Growth hormone bypasses that ceiling entirely. The question of when to move is not just about goals, it is about understanding that you cannot run both at the same time in any meaningful way.

After a single injection of exogenous growth hormone, somatostatin, the brake in the system, inhibits the GHRH pathway by 86 percent. That means the CJC-1295 you are injecting has almost no pathway left to work through. The gas pedal is pressed and the brake is holding 86 percent of the way down. You are spending money on a compound that cannot do its job because the system it works through has been suppressed by the thing you are running alongside it. If your goals require more growth hormone than your pituitary can produce on its own, the answer is to drop the secretagogues and switch to growth hormone, not to run both and assume they add together.

The broader principle underneath all four decisions is the same one. These compounds work by working with your biology, through your receptors, through your feedback loops, through your own pituitary. Every mistake in this category comes from treating them like they are just a weaker version of exogenous growth hormone. They are not a weaker version. They are a different kind of tool entirely, and the moment you lose sight of that, you either buy the wrong form, dose incorrectly, forget to cycle the right compound for the right reason, or waste your money stacking two things that block each other.

The whole reason to use a secretagogue is to stay inside the system. Once you understand that, the four decisions make themselves.

---

References

1. FDA Prescribing Information. EGRIFTA (tesamorelin). 2025 — 52-week continuous dosing, IGF-1 levels maintained at week-26 levels through week 52
2. Bowers CY et al. On the in vitro and in vivo activity of a new synthetic hexapeptide. Endocrinology. 1984 — GHRP/ghrelin receptor agonist mechanism
3. PNAS. Discovery of a functionally selective ghrelin receptor (GHSR1a) ligand. 2022 — β-arrestin mediated GHSR1a desensitization mechanism
4. Veldhuis JD et al. Somatostatin inhibition of GHRH-stimulated GH secretion. J Clin Endocrinol Metab — 86% GHRH pathway inhibition after exogenous GH
5. Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. NEJM. 2007 — Tesamorelin 26-week clinical trial efficacy

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness